Main Office: Loc. Bellaria, 35 - 53018 Sovicille (SI), Italy
e-mail: info@philogen.it – website: www.philogen.com

Philogen
innovating targeting

2026 Swiss Chemical Society (SCS) Industrial Science Award for Samuele Cazzamalli, Head of Research at Philochem

Dr. Samuele Cazzamalli, Head of Research at Philochem, will be awarded the Industrial Science Award 2026 from the Swiss Chemical Society

His research has focused on the discovery of novel tumor-targeting diagnostic and therapeutic agents through the use of DNA-Encoded Chemical Libraries

Siena (Italy), November 28, 2025 – Philogen S.p.A., a clinical-stage biotechnology company focused on antibody and small molecule-based targeted therapeutics, is pleased to announce that in recognition of his many years of research and industrial application of tumor-targeting products, Samuele Cazzamalli will be awarded the Industrial Science Award 2026 from the Swiss Chemical Society (SCS).

The SCS Industrial Science Award is an annual, prestigious honor presented to outstanding industrial chemists in Switzerland. Dr. Cazzamalli was selected for this honor because of his outstanding contributions to the discovery of novel tumor-targeting small molecule ligands through DNA-Encoded Chemical Libraries. Dr. Cazzamalli is invited to give an Award Lecture at the SCS Fall Meeting 2026 in Bern on August 28, 2026, while the award ceremony will take place at the Casino Bern on the evening of Friday, September 18, 2026.

Dr. Cazzamalli is currently the Head of Research at Philochem, the Swiss subsidiary of the Philogen group that acts as a discovery center with a focus on chemical pharmaceutical products and technologies. Dr. Cazzamalli earned his PhD at ETH Zürich under the supervision of Prof. Dario Neri with a thesis on non-internalizing antibody- and small molecule-drug conjugates for the treatment of cancer. Dr. Cazzamalli has published more than 50 articles in international peer-reviewed journals and has brought six compounds in Phase I clinical trials.

Under Dr. Cazzamalli's leadership, the Philochem group has isolated high-affinity small organic ligands from DNA-Encoded Chemical Libraries against various tumor-associated antigens, including FAP, ACP3, and CAIX. By conjugating these ligands to potent payloads, such as cytotoxic drugs or radionuclides, Dr. Cazzamalli's group has developed several promising small-molecule diagnostic and therapeutic compounds for cancer applications.

Philochem has successfully completed four Phase I clinical trials with novel small-molecule radioligands and is launching three additional Phase I clinical trials this year. The company's success is the result of the group's extensive experience in encoded libraries, tumor-targeting conjugate generation, and clinical trial management.

* * *

About Philochem and the Philogen Group

Philochem is a fully owned subsidiary of the Philogen Group, a Swiss-Italian, clinical-stage biotechnology company listed on the Italian Stock Exchange. Philogen is engaged in the discovery and development of novel pharmaceutical and biopharmaceutical products. Philogen's strategy is to selectively deliver bioactive agents (such as radionuclides, cytokines or drugs) to the site of disease using antibodies or small organic ligands. This technology has generated a strong proprietary pipeline of clinical-stage products and preclinical compounds in an array of disease indications. Philogen is headquartered in Siena, Italy, and has research activities at its subsidiary company Philochem near Zurich, Switzerland. Philogen has signed agreements with several major pharmaceutical companies. For more information, please visit www.philogen.com and www.philochem.ch.

* * *

FOR MORE INFORMATION:

Philogen - Investor Relations

IR@philogen.com - Emanuele Puca | Investor Relations